• Users Online: 176
  • Print this page
  • Email this page
Year : 2020  |  Volume : 14  |  Issue : 2  |  Page : 166-169

Experience of using an extracorporeal cytokine hemoadsorber (CytoSorb®) in systemic inflammatory response syndrome after heart transplantation

Advanced Heart Failure and Transplant Clinic, Max Super Specialty Hospital, New Delhi, India

Correspondence Address:
Dr. Kewal Krishan
Advanced Heart Failure and Transplant Clinic, Max Super Specialty Hospital, East Block, 2, Press Enclave Road, Saket, New Delhi - 110 017
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijot.ijot_64_19

Get Permissions

Heart transplantation is well-established and considered the most effective therapy for patients with end-stage heart failure. Systemic inflammatory response syndrome (SIRS) and renal dysfunction after heart transplantation are commonly experienced complications, which may significantly impact on overall survival. The extracorporeal cytokine hemoadsorber (CytoSorb®) is a novel nonpharmacologic hemocompatible adsorber, which has porous polymer beads capable of removing cytokines and other mid-molecular weight toxins from the blood. CytoSorb is a unique hemoadsorber, which has a huge surface area, a broad spectrum of adsorption, and is very easy to set up on any extracorporeal circuit. Here, we report our experience of using CytoSorb in the management of SIRS after heart transplantation in a 28-year-old male.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded107    
    Comments [Add]    

Recommend this journal